Companies
NVS
NOVARTIS AG
Novartis is a pharmaceutical company that develops and commercializes medicines across multiple therapeutic areas and using various drug modalities. The organization operates through distinct business divisions that each manage their development and commercialization independently, with products at various stages from research through commercialization.
$147.85+34.27%1Y
NVS · daily close · illustrative · 0 catalysts marked
Pipeline
Phase 3Relapsing Multiple Sclerosis
Phase 3Prostate Cancer
Phase 3Relapsing Multiple Sclerosis
Phase 2Prostatic Neoplasm
Phase 2Prostatic Cancer, Castration-Resistant
Phase 2Metastatic Castration-resistant Prostate Cancer
Phase 3Oligometastatic Prostate Cancer (OMPC)
Phase 3Prostate Cancer
Phase 3Breast Cancer
Phase 2PIK3CA-related Overgrowth Spectrum (PROS)
Phase 3Advanced HER2+Breast Cancer
Phase 2/3Lymphatic Malformations
Phase 2Advanced Breast Cancer
Phase 2Breast Cancer
Phase 3Early Breast Cancer
Phase 3Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
Phase 2Chronic Myelogenous Leukemia - Chronic Phase
Phase 3Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
Phase 3Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
Phase 3Asthma
Phase 3Immune Thrombocytopenia
Phase 3Sickle Cell Disease
Phase 3Sickle Cell Disease (SCD)
Phase 3Differentiated Thyroid Cancer (DTC)
Phase 3Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
Phase 3Non-Small Cell Lung Cancer
Phase 3Chronic Spontaneous Urticaria (CSU)
Phase 3Tuberous Sclerosis Complex
Phase 3Early Breast Cancer
Phase 3Breast Cancer
Phase 2Advanced HR+/HER2- Breast Cancer
Phase 2Advanced CCNE1-amplified Solid Tumors
Phase 2Metastatic Castration-resistant Prostate Cancer
Phase 2Advanced Breast Cancer
Phase 2Breast Cancer
Phase 3Early Breast Cancer
Phase 3Systemic Lupus Erythematosus
Phase 3Warm Autoimmune Hemolytic Anemia (wAIHA)
Phase 3Lupus Nephritis
Phase 2Diffuse Cutaneous Systemic Sclerosis
Phase 2Immune Thrombocytopenia
Phase 3Primary Sjogren's Disease
Phase 3Lupus Nephritis
Phase 3Lupus Nephritis
Phase 3Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
Phase 3Hypercholesterolemia
Phase 3Atherosclerotic Cardiovascular Disease (ASCVD)
Phase 3Heterozygous or Homozygous Familial Hypercholesterolemia
Phase 3Familial Hypercholesterolemia - Heterozygous
Phase 3Acute Coronary Syndrome
Phase 3Primary Prevention of Atherosclerotic Cardiovascular Disease
Phase 3Multiple Sclerosis
Phase 2Glomerulonephritis, IGA
Phase 2Immunoglobulin A Nephropathy
Phase 3IC-MPGN
Phase 3C3G
Phase 3Atypical Hemolytic Uremic Syndrome
Phase 3Primary Immunoglobulin A Nephropathy (IgAN)
Phase 3Paroxysmal Nocturnal Hemoglobinuria
Phase 2Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis
Phase 3Generalized Myasthenia Gravis
Phase 3Atypical Hemolytic Uremic Syndrome
Phase 3Relapsing Multiple Sclerosis
Phase 3Follicular Lymphoma (FL)
Phase 3Early Breast Cancer
Phase 2Breast Cancer
Phase 2Advanced HR+/HER2- Breast Cancer
Phase 2Advanced CCNE1-amplified Solid Tumors
Phase 2Metastatic Castration-resistant Prostate Cancer
Phase 3Early Breast Cancer
Phase 3Primary IgA Nephropathy
Phase 3Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 3C3 Glomerulopathy
Phase 3Immune-complex-membranoproliferative Glomerulonephritis
Phase 3Chronic Spontaneous Urticaria
Phase 3Chronic Spontaneous Urticaria
Phase 3Follicular Lymphoma (FL)
Phase 3Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
Phase 3Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
Phase 3Relapsing Multiple Sclerosis
Phase 3Somatostatin Receptor Positive (SSTR+)
Phase 3Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Phase 3Relapsing Multiple Sclerosis (RMS)
Phase 3Relapsing Multiple Sclerosis (RMS)
Phase 3Chronic Spontaneous Urticaria
Phase 3Spinal Muscular Atrophy
Phase 3Primary Myelofibrosis (PMF)
Phase 3Post-polycythemia Vera Myelofibrosis (PPV-MF)
Phase 3Post-essential Thrombocythemia Myelofibrosis
Phase 3Hematologic Malignancy
Phase 3Solid Tumor
Phase 3Advanced Malignancies
Phase 3Myelofibrosis
Phase 3Cardiovascular Disease and Lipoprotein(a)
Phase 3Atherosclerotic Cardiovascular Disease
Phase 3Advanced HER2+Breast Cancer
Phase 3Asthma
Phase 3Chronic Spontaneous Urticaria (CSU)
Phase 3Chronic Inducible Urticaria
Phase 3Relapsing Multiple Sclerosis
Phase 2Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)
Phase 3Generalized Myasthenia Gravis
Phase 3Secondary Progressive Multiple Sclerosis (SPMS)
Phase 3Generalized Myasthenia Gravis
Phase 3Secondary Progressive Multiple Sclerosis (SPMS)
Phase 3Hidradenitis Suppurativa
Phase 3Hidradenitis Suppurativa
Phase 3Relapsing Multiple Sclerosis
Phase 3Early Breast Cancer
Phase 2Melanoma
Phase 2KRAS G12C Mutant Solid Tumors
Phase 2Colorectal Cancer
Phase 2Colorectal Carcinoma
Phase 2Colorectal Neoplasms
Phase 2Colorectal Tumors
Phase 2Neoplasms, Colorectal
Phase 2Advanced HR+/HER2- Breast Cancer
Phase 2Advanced CCNE1-amplified Solid Tumors
Phase 2Non-Small Cell Lung Cancer
Phase 3Primary Myelofibrosis (PMF)
Phase 3Post-polycythemia Vera Myelofibrosis (PPV-MF)
Phase 3Post-essential Thrombocythemia Myelofibrosis
Phase 3Myelofibrosis
Phase 3Relapsing Multiple Sclerosis
Phase 3Multiple Sclerosis (MS)
Phase 3Prostate Cancer
Phase 3Relapsing Multiple Sclerosis
Phase 3Relapsing Multiple Sclerosis
Phase 3Follicular Lymphoma (FL)
Phase 3Cardiovascular Disease and Lipoprotein(a)
Phase 2Melanoma
Phase 2KRAS G12C Mutant Solid Tumors
Phase 2Colorectal Cancer
Phase 2Colorectal Carcinoma
Phase 2Colorectal Neoplasms
Phase 2Colorectal Tumors
Phase 2Neoplasms, Colorectal
Phase 3Differentiated Thyroid Cancer (DTC)
Phase 2Non-Small Cell Lung Cancer
Phase 3Advanced HER2+Breast Cancer
Phase 3Huntington Disease
Phase 2Immunoglobulin A Nephropathy (IgAN)
Phase 3Kidney Diseases
Phase 3Kidney Diseases, Chronic
Phase 3Urological Diseases
Phase 3Glomerulonephritis
Phase 3Glomerular Disease
Phase 3Glomerulonephritis, IGA
Phase 3Glomerulopathy
Phase 3Immunoglobulin Disease
Phase 2/3Prostate Cancer
Phase 2Extensive Stage Small Cell Lung Cancer
Phase 2Breast Cancer
Phase 2Metastatic Castration-resistant Prostate Cancer
Phase 2Extensive Stage Small Cell Lung Cancer
Phase 2Breast Cancer
Phase 2Metastatic Castration-resistant Prostate Cancer
Phase 2Solid Tumor
Phase 2Prostate Cancer
Phase 2Solid Tumor
Phase 2Prostatic Neoplasm
Phase 2Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Phase 2PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
Phase 2Chronic Myeloid Leukemia (CML)
Phase 2PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
Phase 2Metastatic Castration-resistant Prostate Cancer
Phase 2Metastatic Castration-resistant Prostate Cancer
Phase 2Prostate Cancer Metastatic
Phase 2Prostate Cancer Metastatic
Phase 2Myeloid Leukemia, Philadelphia Positive
Phase 2Myeloid Leukemia, Philadelphia Positive
Phase 2Chronic Myelogenous Leukemia
Phase 2Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive
Phase 2Extensive Stage Small Cell Lung Cancer
Phase 2IgA Nephropathy
Phase 2Focal Segmental Glomerulosclerosis
Phase 2Alport Syndrome
Phase 2Diabetic Kidney Disease
Phase 2Diabetic Nephropathy Type 2
Phase 2Immunoglobulin A Nephropathy
Phase 2Chagas Disease
Phase 2IgA Nephropathy
Phase 2IgA Nephropathy
Phase 2Breast Cancer
Phase 2Breast Cancer
Phase 2Advanced Solid Tumors Which Are cMET-dependent
Phase 2KRAS G12C Mutant Solid Tumors
Phase 2Colorectal Cancer
Phase 2Colorectal Carcinoma
Phase 2Colorectal Neoplasms
Phase 2Colorectal Tumors
Phase 2Neoplasms, Colorectal
Phase 2Non-Small Cell Lung Cancer
Phase 2Hidradenitis Suppurativa
Phase 2Retinitis Pigmentosa
Phase 2Cryptosporidiosis
Phase 2FLT3-mutated Acute Myeloid Leukemia
Phase 2Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Phase 2FLT3-mutated Acute Myeloid Leukemia
Phase 2Lipoprotein Disorder
Phase 2Metastatic Uveal Melanoma
Phase 2Cryptosporidiosis
Phase 2Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Phase 2PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
Phase 2Advanced Solid Tumor
Phase 2Diffuse Large B-Cell Lymphoma
Phase 2Lymphoma, T-Cell
Phase 2Mesothelioma, Malignant
Phase 2Prostatic Neoplasms, Castration-Resistant
Phase 2Endometrial Cancer
Phase 2Ovarian Clear Cell Carcinoma
Phase 2Metastatic Castration-resistant Prostate Cancer
Phase 2FLT3-mutated Acute Myeloid Leukemia
Phase 2Dengue
Phase 2FLT3-mutated Acute Myeloid Leukemia
Phase 2Geographic Atrophy Secondary to Age-related Macular Degeneration
Phase 2Advanced Solid Tumors Which Are cMET-dependent
Phase 2Atopic Dermatitis
Phase 2ANCA Associated Vasculitis (AAV)
Phase 2Asthma
Phase 2Asthma
Phase 2Advanced HR+/HER2- Breast Cancer
Phase 2Advanced CCNE1-amplified Solid Tumors
Phase 2Metastatic Castration-resistant Prostate Cancer
Phase 2Schizophrenia
Phase 2Chronic Lymphocytic Leukemia
Phase 2Small Lymphocytic Lymphoma
Phase 2Diffuse Large B-Cell Lymphoma
Phase 2Acute Lymphoblastic Leukemia
Phase 2Large B-cell Lymphoma
Phase 2Uncomplicated Plasmodium Falciparum Malaria
Phase 2Age-Related Macular Degeneration
Phase 2Lupus Nephritis
Phase 2Lupus Nephritis
Phase 2Sickle Cell Disease
Phase 2Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
Phase 2KRAS G12C Mutant Solid Tumors
Phase 2Carcinoma, Colorectal
Phase 2Cancer of Lung
Phase 2Cancer of the Lung
Phase 2Lung Cancer
Phase 2Neoplasms, Lung
Phase 2Neoplasms, Pulmonary
Phase 2Pulmonary Cancer
Phase 2Pulmonary Neoplasms
Phase 2Colorectal Cancer
Phase 2Colorectal Carcinoma
Phase 2Colorectal Neoplasms
Phase 2Colorectal Tumors
Phase 2Neoplasms, Colorectal
Phase 2Non-Small Cell Lung Cancer
Phase 2Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Phase 2Prostatic Cancer, Castration-Resistant
Phase 2Progressive Metastatic Castrate Resistant Prostate Cancer
Phase 2Progressive Metastatic Castrate Resistant Prostate Cancer
Phase 2Progressive Metastatic Castrate Resistant Prostate Cancer
Phase 2Uncomplicated Plasmodium Falciparum Malaria
Phase 2Uncomplicated Plasmodium Falciparum Malaria
Phase 2Breast Cancer
Phase 2Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies
Phase 2Hidradenitis Suppurativa
Phase 2Hidradenitis Suppurativa
Phase 2Healthy Volunteers, Pulmonary Arterial Hypertension
Phase 2Melanoma
Phase 2Chagas Disease
Phase 2Melanoma
Phase 2Hidradenitis Suppurativa
Phase 2Hidradenitis Suppurativa
Phase 2NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations
Phase 2Still´s Disease
Phase 2FLT3-mutated Acute Myeloid Leukemia
Phase 2FLT3-mutated Acute Myeloid Leukemia
Phase 2Advanced Solid Tumors Which Are cMET-dependent
Phase 2Advanced Solid Tumors Which Are cMET-dependent
Phase 2Aortic Stenosis
Phase 2Prostatic Neoplasm
Phase 2Atrial Fibrillation
Phase 2Hypertension
Phase 2Scleroderma, Diffuse
Phase 2Lupus Erythematosus, Systemic
Phase 2Lupus Nephritis
Phase 2ANCA Associated Vasculitis (AAV)
Phase 2Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD)
Phase 2Idiopathic Inflammatory Myopathies
Phase 2Progressive Multiple Sclerosis
Phase 2Relapsing Multiple Sclerosis
Phase 2Chronic Lymphocytic Leukemia
Phase 2Small Lymphocytic Lymphoma
Phase 2Diffuse Large B-Cell Lymphoma
Phase 2Acute Lymphoblastic Leukemia
Phase 2Large B-cell Lymphoma
Phase 2Scleroderma, Diffuse
Phase 2Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis
Phase 2Uncomplicated Plasmodium Falciparum Malaria
Phase 2Progressive Metastatic Castrate Resistant Prostate Cancer
Phase 2Acute Kidney Injury Due to Sepsis
Phase 2KRAS G12C Mutant Solid Tumors
Phase 2Carcinoma, Colorectal
Phase 2Cancer of Lung
Phase 2Cancer of the Lung
Phase 2Lung Cancer
Phase 2Neoplasms, Lung
Phase 2Neoplasms, Pulmonary
Phase 2Pulmonary Cancer
Phase 2Pulmonary Neoplasms
Phase 2Non-Small Cell Lung Cancer
Phase 2KRAS G12C Mutant Solid Tumors
Phase 2Carcinoma, Colorectal
Phase 2Cancer of Lung
Phase 2Cancer of the Lung
Phase 2Lung Cancer
Phase 2Neoplasms, Lung
Phase 2Neoplasms, Pulmonary
Phase 2Pulmonary Cancer
Phase 2Pulmonary Neoplasms
Phase 2Non-Small Cell Lung Cancer
Phase 2Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Phase 2Advanced Solid Tumor
Phase 2Diffuse Large B-Cell Lymphoma
Phase 2Lymphoma, T-Cell
Phase 2Mesothelioma, Malignant
Phase 2Prostatic Neoplasms, Castration-Resistant
Phase 2Endometrial Cancer
Phase 2Ovarian Clear Cell Carcinoma
Phase 2Metastatic Castration-resistant Prostate Cancer
Phase 2Progressive Metastatic Castrate Resistant Prostate Cancer
Phase 2Progressive Metastatic Castrate Resistant Prostate Cancer
Phase 2Progressive Metastatic Castrate Resistant Prostate Cancer
Phase 2Progressive Metastatic Castrate Resistant Prostate Cancer
Phase 2Progressive Metastatic Castrate Resistant Prostate Cancer
Phase 2Sjögrens Disease
Phase 2Systemic Lupus Erythematosus
Phase 2Rheumatoid Arthritis
Phase 2Huntington Disease
Catalyst Calendar
No catalyst events on record for yet. Check back after the next daily ingest.